← Back to Screener
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share (OACC)
Price$10.70
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-11.59%
Price vs S&P 500 (4W)-4.52%
VGM Score39.87
Market Capitalization$262.54M
All Metrics
Indicated Dividend (Annual)$0.00
Price vs S&P 500 (YTD)-8.45%
10-Day Avg Trading Volume0.00M
Quick Ratio (Quarterly)1.09x
3-Month Avg Trading Volume0.04M
52-Week High$10.74
26-Week Price Return2.10%
13-Week Price Return0.75%
Current Ratio (Quarterly)1.09x
3-Month Return Std Dev6.65%
Year-to-Date Return0.95%
5-Day Price Return-0.47%
Month-to-Date Return0.66%
Price vs S&P 500 (13W)-8.43%
Beta0.02x
52-Week Low$10.30
mGradeD
vgmGradeD
Show chart for
Industry Peers — Blank Checks / SPACs(771)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
OACCOaktree Acquisition Corp. III Life Sciences Class A Ordinary Share | — | — | D | $10.70 |
| KCAC.WSKensington Capital Acquisition Corp. VI Class 1 redeemable warrants, each exercisable for one Class A ordinary share at an exercise price of $11.50 | F | A | A | $0.52 |
| CAEPCantor Equity Partners III, Inc. Class A Ordinary Shares | — | — | F | $7.52 |
| WLACWillow Lane Acquisition Corp. Class A Ordinary Shares | — | B | A | $34.05 |
| AACIUArmada Acquisition Corp. III Units | — | A | A | $10.08 |
| BACQRInflection Point Acquisition Corp. IV Right | — | D | D | $0.00 |
| BACQUInflection Point Acquisition Corp. IV Unit | — | D | D | $0.00 |
| AACIArmada Acquisition Corp. III Class A Ordinary Share | — | — | D | $9.96 |
| DMIIDrugs Made In America Acquisition II Corp. Ordinary Shares | — | — | C | $10.06 |
| DMIIRDrugs Made In America Acquisition II Corp. Right | — | — | C | $0.07 |
| DMIIUDrugs Made In America Acquisition II Corp. Unit | — | — | C | $10.15 |
About
Oaktree Acquisition Corp III Life Sciences is a special purpose acquisition company (SPAC) established to identify, acquire, and operate a business in the life sciences sector. The blank-check company was formed to raise capital through a public offering for the purpose of merging with or acquiring an operating company in life sciences.